Trip Anouk Kirsten, Hedegaard Dahlrot Rikke, Aaquist Haslund Charlotte, Muhic Aida, Rosendal Korshøj Anders, Laursen René Johannes, Rom Poulsen Frantz, Skjøth-Rasmussen Jane, Lukacova Slavka
Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
Department of Oncology, Odense University Hospital, Odense, Denmark.
Neurooncol Pract. 2024 Mar 9;11(4):421-431. doi: 10.1093/nop/npae020. eCollection 2024 Aug.
This Danish cohort study aims to (1) compare patterns of care (POC) and survival of patients with multifocal glioblastoma (mGBM) to those with unifocal glioblastoma (uGBM), and (2) explore the association of patient-related factors with treatment assignment and prognosis, respectively, in the subgroup of mGBM patients.
Data on all adults with newly diagnosed, pathology-confirmed GBM between 2015 and 2019 were extracted from the Danish Neuro-Oncology Registry. To compare POC and survival of mGBM to uGBM, we applied multivariable logistic and Cox regression analysis, respectively. To analyze the association of patient-related factors with treatment assignment and prognosis, we established multivariable logistic and Cox regression models, respectively.
In this cohort of 1343 patients, 231 had mGBM. Of those, 42% underwent tumor resection and 41% were assigned to long-course chemoradiotherapy. Compared to uGBM, mGBM patients less often underwent a partial (odds ratio [OR] 0.4, 95% confidence interval [CI] 0.2-0.6), near-total (OR 0.1, 95% CI 0.07-0.2), and complete resection (OR 0.1, 95% CI 0.07-0.2) versus biopsy. mGBM patients were furthermore less often assigned to long-course chemoradiotherapy (OR 0.6, 95% CI 0.4-0.97). Median overall survival was 7.0 (95% CI 5.7-8.3) months for mGBM patients, and multifocality was an independent poor prognostic factor for survival (hazard ratio 1.3, 95% CI 1.1-1.5). In mGBM patients, initial performance, O[6]-methylguanine-DNA methyltransferase promotor methylation status, and extent of resection were significantly associated with survival.
Patients with mGBM were treated with an overall less intensive approach. Multifocality was a poor prognostic factor for survival with a moderate effect. Prognostic factors for patients with mGBM were identified.
这项丹麦队列研究旨在:(1)比较多灶性胶质母细胞瘤(mGBM)患者与单灶性胶质母细胞瘤(uGBM)患者的治疗模式(POC)和生存率;(2)在mGBM患者亚组中分别探讨患者相关因素与治疗分配及预后的关联。
从丹麦神经肿瘤登记处提取2015年至2019年间所有新诊断、经病理确诊的成人大脑胶质瘤患者的数据。为比较mGBM与uGBM的治疗模式和生存率,我们分别应用了多变量逻辑回归分析和Cox回归分析。为分析患者相关因素与治疗分配及预后的关联,我们分别建立了多变量逻辑回归模型和Cox回归模型。
在这1343例患者队列中,231例患有mGBM。其中,42%接受了肿瘤切除术,41%被分配接受长疗程放化疗。与uGBM相比,mGBM患者接受部分切除(优势比[OR]0.4,95%置信区间[CI]0.2 - 0.6)、近全切除(OR 0.1,95%CI 0.07 - 0.2)和完全切除(OR 0.1,95%CI 0.07 - 0.2)而非活检的比例更低。此外,mGBM患者被分配接受长疗程放化疗的比例也更低(OR 0.6,95%CI 0.4 - 0.97)。mGBM患者的中位总生存期为7.0(95%CI 5.7 - 8.3)个月,多灶性是生存的独立不良预后因素(风险比1.3,95%CI 1.1 - 1.5)。在mGBM患者中,初始身体状况、O[6]-甲基鸟嘌呤-DNA甲基转移酶启动子甲基化状态和切除范围与生存显著相关。
mGBM患者接受的总体治疗强度较低。多灶性是生存的不良预后因素,影响程度中等。确定了mGBM患者的预后因素。